MARKET

BIIB

BIIB

Biogen
NASDAQ

Real-time Quotes | Nasdaq Last Sale

289.75
+1.21
+0.42%
Opening 10:24 08/14 EDT
OPEN
287.99
PREV CLOSE
288.54
HIGH
290.00
LOW
287.79
VOLUME
118.12K
TURNOVER
--
52 WEEK HIGH
374.99
52 WEEK LOW
215.78
MARKET CAP
45.87B
P/E (TTM)
8.49
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 33 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BIIB stock price target is 307.00 with a high estimate of 386.00 and a low estimate of 228.00.

EPS

BIIB News

More
Genomic Medicine: Summer 2020 Update
Seeking Alpha - Article · 1d ago
Biotech Stock Roundup: BMY & REGN Q2 Earnings, Gilead NDA for Coronavirus Drug
Zacks · 1d ago
Health-Care Reform Under Biden/Harris Would Be “Measured,” RBC Says
marketwatch.com · 2d ago
Biogen: An Undervalued Opportunity In An Overpriced Market
<ul><li>Biogen has an impressive portfolio of assets that it is continuing to work towards developing. The most exciting of these is Aducanumab.</li><li>Even if Aducanumab isn't approved, the company has an incredibly exciting asset portfolio. That will continue to support strong earnings.</li><li>Going forward, the company will continue generating strong earnings. These strong earnings will continue to generate strong shareholder returns.</li></ul>
Seekingalpha · 3d ago
Biogen: An Undervalued Opportunity In An Overpriced Market
Seeking Alpha - Article · 3d ago
Alzheimer's in Focus as Biogen's Aducanumab Gets Priority Tag
Zacks · 3d ago
Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
<ul><li>BioKangtai, a Guangdong vaccine company, in-licensed rights to develop, manufacture and market AstraZeneca's COVID-19 vaccine in China.</li><li>Biogen announced a $2 billion blockbuster deal to partner Denali Therapeutics' potential Parkinson's Disease therapy.</li><li>Nanjing Simcere Pharma in-licensed Greater China rights to trilaciclib from North Carolina's GI Therapeutics in a $170 million agreement.</li></ul>
Seekingalpha · 4d ago
Week In Review: BioKangtai Acquires China Rights To AstraZeneca's COVID-19 Vaccine
Seeking Alpha - Article · 4d ago

Industry

Pharmaceuticals
-0.02%
Pharmaceuticals & Medical Research
-0.11%

Hot Stocks

Symbol
Price
%Change

About BIIB

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
More

Webull offers kinds of Biogen Inc stock information, including NASDAQ:BIIB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIIB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BIIB stock methods without spending real money on the virtual paper trading platform.